SCHEMBL2825852

SCHEMBL2825852

COc1ccc(C(N)=C2C(=O)Nc3ccccc32)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.75
▸ MAPT P10636 5/20 0.52
▸ ALDH1A1 P00352 4/20 0.52
▸ GAA P10253 2/20 0.52
▸ TTR P02766 1/20 0.52
▸ LRRK2 Q5S007 1/20 0.52
▸ APP P05067 1/20 0.48
▸ SNCA P37840 1/20 0.48
▸ IDO1 P14902 2/20 0.47
▸ TDO2 P48775 1/20 0.47
▸ TNKS2 Q9H2K2 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MDM2 Q00987 1/20 0.44
▸ NTSR1 P30989 1/20 0.44
▸ CSNK1D P48730 3/20 0.43
▸ CSNK1A1 P48729 2/20 0.43
▸ CSNK1E P49674 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ GMNN O75496 1/20 0.43
▸ LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13207340 1.00 TDP1 (0.75) TDP1MAPTALDH1A1GAATTR
SCHEMBL2825850 1.00 TDP1 (0.75) TDP1MAPTALDH1A1GAATTR
SCHEMBL29670839 0.86 TDP1 (1.00) TDP1MAPTALDH1A1GAATTR
SCHEMBL725960 0.86 TDP1 (1.00) TDP1MAPTALDH1A1GAATTR
SCHEMBL4999345 0.84 TDP1 (0.52) TDP1MAPTALDH1A1LRRK2IDO1
SCHEMBL2829327 0.84 TDP1 (0.50) TDP1MAPTALDH1A1LRRK2IDO1
SCHEMBL2829329 0.84 TDP1 (0.50) TDP1MAPTALDH1A1LRRK2IDO1
SCHEMBL6406357 0.83 TDP1 (0.75) TDP1MAPTALDH1A1GAATTR
SCHEMBL2826121 0.82 PLK4 (0.50) TDP1MAPTALDH1A1LRRK2IDO1
SCHEMBL13207305 0.82 PLK4 (0.50) TDP1MAPTALDH1A1LRRK2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781475-B2 Oxindoles as kinase inhibitors MERCK PATENT GMBH (DE) 2010-08-24 — — US claimed
US-20100197757-A1 OXINDOLES AS KINASE INHIBITORS BURGDORF LARS THORE 2010-08-05 — — US claimed
US-20090131506-A1 Oxindoles as Kinase Inhibitors MERCK PATENT GMBH (DE) 2009-05-21 — — US claimed
EP-1891008-A1 OXINDOLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2008-02-27 — — EP claimed
WO-2006131186-A1 OXINDOLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2006-12-14 — — WO claimed
US-7781475-B2 Oxindoles as kinase inhibitors MERCK PATENT GMBH (DE) 2010-08-24 — — US disclosed
US-20100197757-A1 OXINDOLES AS KINASE INHIBITORS BURGDORF LARS THORE 2010-08-05 — — US disclosed
EP-1891008-B1 OXINDOLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2010-06-30 — — EP disclosed
US-20090131506-A1 Oxindoles as Kinase Inhibitors MERCK PATENT GMBH (DE) 2009-05-21 — — US disclosed
EP-1891008-A1 OXINDOLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2008-02-27 — — EP disclosed
WO-2006131186-A1 OXINDOLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2006-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197757-A1 OXINDOLES AS KINASE INHIBITORS MAP4K2, MAP3K20, MAP3K1 TDP1 2148/4885MAPT 823/4885ALDH1A1 2486/4885
US-20090131506-A1 Oxindoles as Kinase Inhibitors MAP4K2, MAP3K20, MAP3K1 TDP1 2148/4885MAPT 823/4885ALDH1A1 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback